MeiraGTx adds Alan M. Sebulsky, former Adage Capital manager, to board
The genetic medicines company named Sebulsky a Class I director effective September 23, 2026, with a term running until the 2028 annual meeting.
SEC filing
Latest
2 stories
Wednesday, September 23
Thursday, August 13
MeiraGTx reports Q2 2026 results, advances bota-vec and AAV2-hAQP1 toward filings
The company completed the bota-vec acquisition from J&J, finished enrollment in its pivotal AQUAx2 study, and secured up to $400 million from Oberland Capital.
SEC filing